Litcius/Paper detail

Evaluation of Antimicrobial Susceptibility Testing Methods for Burkholderia cenocepacia and Burkholderia multivorans Isolates from Cystic Fibrosis Patients

Holly K. Huse, Mark J. Lee, Mandy Wootton, Susan E. Sharp, Maria Traczewski, John J. LiPuma, Peter Jorth

2021Journal of Clinical Microbiology19 citationsDOIOpen Access PDF

Abstract

isolates collected from people with CF. The following drugs were evaluated in triplicate: chloramphenicol (CAM), ceftazidime (CAZ), meropenem (MEM), trimethoprim-sulfamethoxazole (TMP-SMX), minocycline (MIN), levofloxacin (LVX), ciprofloxacin (CIP), and piperacillin-tazobactam (PIP-TAZ). BMD reproducibility was ≥ 95% for MEM and MIN only, and MicroScan WalkAway reproducibility was similar to BMD. DD reproducibility was < 90% for all drugs tested when a 3 mm cut-off was applied. When comparing the accuracy of DD to BMD, only MEM met all acceptance criteria. TMP-SMX and LVX had high minor errors, CAZ had unacceptable very major errors (VME), and MIN, PIP-TAZ, and CIP had both unacceptable minor errors and VMEs. For MicroScan WalkAway, no drugs met acceptance criteria. Analyses also showed that errors were not attributed to one species. In general, our data agree with EUCAST recommendations.

Topics & Concepts

Burkholderia cenocepaciaMicrobiologyCystic fibrosisBurkholderia cepacia complexCeftazidimeMedicineReproducibilityBroth microdilutionAntimicrobialCiprofloxacinBurkholderiaAntibioticsLevofloxacinBiologyAntibacterial agentEtestImipenemMeropenemCystic Fibrosis Research AdvancesSinusitis and nasal conditionsBacterial Identification and Susceptibility Testing